In his decades-long career in tech journalism, Dennis has written about nearly every type of hardware and software. He was a founding editor of Ziff Davis’ Computer Select in the 1990s, senior ...
REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today ...
Twelve Indians were among 13 people killed in an explosion at a factory in the Ras Laffan Industrial City in Qatar, officials said on Monday. "Qatari authorities have confirmed that 12 Indian ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Ladies and gentlemen, thank you for standing by. Welcome to the Cardiff Oncology ASCO Data Presentation Conference Call. [Operator Instructions] Please be advised that today's conference is being ...
An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...
A shift in the way people think about and treat pancreatic cancer could be on the horizon based on positive results from the pivotal randomized Phase III RASolute 302 trial comparing daraxonrasib to ...
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.
Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trial. Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib ...
Everything is for sale outside of the Times Square Swatch store right now, where dozens of people are camped out in anticipation of Swatch x Audemars Piguet Royal Pop’s drop. The queue began to take ...
The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...
The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results